AACR-NCI-EORTC: Antitumor Activity of STRO-002 (Poster)


Antitumor activity of STRO-002, a novel anti-folate receptor-⍺ (FolR⍺) antibody-drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC). Poster presented during the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held October 26 – 30, 2019 in the Hynes Convention Center Boston, MA.

Clinical trials
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers – NCT03748186.

Reference
Uyar D, Schilder R, Naumann RW, Braiteh F, Hamilton E, Diab S, Moroney J, Penson R, et al. Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC).C095 | Poster Session C: Tubulin-interacting Agents | Level 2 – Hall D |Tuesday, Oct 29 | 12:30pm – 4:00pm. | AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, held October 26 – 30, 2019 in the Hynes Convention Center Boston, MA.